TACE Combined With Lenvatinib and PD-1 Inhibitor for Ruptured Hepatocellular Carcinoma

NARecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 13, 2024

Primary Completion Date

December 30, 2025

Study Completion Date

August 30, 2026

Conditions
Hepatocellular CarcinomaTranscatheter Arterial ChemoembolizationAnti-PD1 AntibodyLenvatinib
Interventions
PROCEDURE

TACE

TACE procedure was a 2.8-F microcatheter was super-selectively inserted into the tumor feeding artery using the coaxial technique. Then a combination of lipiodol (5-15 ml), lobaplatin (30-50 mg), and Pirarubicin (30-50 mg) was infused into each tumor. We defined technical success as complete embolization of the tumor-feeding artery resulting in no tumor staining observed by angiogram at the end of procedure.

DRUG

Lenvatinib

(12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg) orally once a day

DRUG

PD-1 Inhibitors

Tislelizumab (200mg intravenously every 3 weeks), Sintilimab (200mg intravenously every 3 weeks), Camrelizumab (200mg intravenously every 3 weeks)

Trial Locations (1)

100853

RECRUITING

Qunfang Zhou, Beijing

All Listed Sponsors
lead

Sun Yat-sen University

OTHER